Knight Therapeutics (GUD) AGM 2025 summary

Opening remarks and agenda

• Meeting held via live audio webcast to encourage broad shareholder participation and facilitate voting and Q&A opportunities.

• Formal business included director elections, auditor appointment, and share plan approval, followed by a review of 2024 events.

Financial performance review

• Achieved record-high adjusted revenues of over CAD 365 million and adjusted EBITDA of approximately CAD 58 million for 2024.

• Three-year CAGR of 15% for both adjusted revenues and EBITDA; key products grew 16% over prior year.

• Adjusted revenues grew 6% year-over-year; adjusted EBITDA decreased 4% due to investments in new launches.

• Strong balance sheet with over CAD 142 million in cash, financial assets of almost CAD 135 million, and debt just over CAD 40 million.

• Net asset value just under CAD 800 million; capital market cap recently at CAD 615 million.

Board and executive committee updates

• Directors nominated and elected for the ensuing year: Jonathan Goodman, James Gale, Samira Sakhia, Robert Landy, Michael Tremblay, Nicolas Sujoy, and Janice Murray.

• Management team and board have significant experience in the pharmaceutical sector and strong insider holdings.